Study design and treatments
cough
ASTHMA
The study was designed as a double-blind, randomized, placebo-controlled, two-sequence, two-period crossover study (Fig. Study design and study procedures. Patients were randomized either to the treatment sequence ‘Regular use of any systemic or topical cough-modulating drugs, e.g., acetylcholine esterase inhibitors or gabapentin, within the 14 days before the first administration of study medication or during the study represented an exclusion criterion. Occasional intake of antitussives, e.g., opioids once or twice per week, was acceptable, but only > 48 h before cough monitoring to minimize the impact on study results. Stable background treatment for possible underlying cough etiologies, e.g., corticosteroids in case of asthma, was also acceptable. Based on preclinical data, no pharmacokinetic interactions with filapixant were expected in such cases.